Tanaka Satoshi, Asakawa Ryo, Komuta Kiyohide, Tanizaki Satoshi, Kanai Tomohiro, Kuroyama Muneyoshi, Shimazu Kohki, Uchida Junji, Yakushijin Takayuki, Ueno Kiyonobu
Department of Respiratory Medicine, Osaka General Medical Center, Osaka, Japan.
Department of Pathology, Osaka General Medical Center, Osaka, Japan.
Respir Med Case Rep. 2020 Oct 20;31:101266. doi: 10.1016/j.rmcr.2020.101266. eCollection 2020.
Immune checkpoint inhibitors (ICIs) improved the prognosis of patients with advanced lung cancers. The combination therapy of cytotoxic drugs and ICI is approved as first-line chemotherapy in non-small-cell lung cancer (NSCLC) and extensive disease small-cell lung cancer (ED-SCLC). It has been reported various immune-related adverse events (irAEs). We herein report a 65-year-old man with NSCLC who developed hepatitis and pancreatitis simultaneously during the combination immunochemotherapy. In the treatment of hepatitis and pancreatitis, the clinical course was different. In this report, the importance of accurate diagnosis through detailed examination and treatment priority depending on the severity of the symptoms is indicated.
免疫检查点抑制剂（ICIs）改善了晚期肺癌患者的预后。细胞毒性药物与ICIs的联合疗法已被批准用于非小细胞肺癌（NSCLC）和广泛期小细胞肺癌（ED-SCLC）的一线化疗。已有多种免疫相关不良事件（irAEs）的报道。我们在此报告一名65岁的NSCLC男性患者，在免疫化学联合治疗期间同时发生了肝炎和胰腺炎。在肝炎和胰腺炎的治疗中，临床过程有所不同。本报告指出了通过详细检查进行准确诊断以及根据症状严重程度确定治疗优先级的重要性。
